Story perspectives

Australia Faces Drug Pricing Pressures Amid Trump Talks

9/28/2025

Summary

Story summary

Australian Health Minister Mark Butler warns President Donald Trump's drug-pricing order could strain the Pharmaceutical Benefits Scheme (PBS).
Eli Lilly's CEO calls the UK 'worst in Europe' on pricing, citing withdrawals.
Moderna's UK chief defends ongoing investments, stressing a long-term government partnership.
Prime Minister Anthony Albanese's government is exploring PBS reforms to maintain access amid pricing pressures before Trump talks.

History

Historical Context

The Pharmaceutical Benefits Scheme (PBS) was established in Australia in 1948 to subsidize medications. Despite its intent to ensure affordable access, it has faced challenges, including pharmaceutical companies like Eli Lilly withdrawing products over pricing disputes. Health Minister Mark Butler's recent comments on President Trump's drug-pricing order highlight ongoing tensions between government policies and pharmaceutical interests, potentially leading to significant reforms affecting healthcare access.

1 of 2

Story summary

Australian Health Minister Mark Butler warns President Donald Trump's drug-pricing order could strain the Pharmaceutical Benefits Scheme (PBS).
Eli Lilly's CEO calls the UK 'worst in Europe' on pricing, citing withdrawals.
Moderna's UK chief defends ongoing investments, stressing a long-term government partnership.
Prime Minister Anthony Albanese's government is exploring PBS reforms to maintain access amid pricing pressures before Trump talks.

1 / 2